Three ASX Healthcare Stocks Drop Today: Vectus, Tissue Repair and Clever Culture Shares

Sonal Goyal

12 November 2026 09:34 PM AEDT

Three ASX Healthcare Stocks Drop Today: Vectus, Tissue Repair and Clever Culture Shares

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Vectus Biosystems (ASX:VBS) closed at $0.05, Tissue Repair (ASX:TRP) at $0.11 and Clever Culture Systems (ASX:CC5) at $0.014 on 12 November 2026.
The falls were 16.67%, 15.39% and 12.50% respectively, while the S&P/ASX 200 closed at 9,146.80.
None of the three companies' recent updates was released on 12 November, so the share price moves are not linked to those announcements.

Three ASX healthcare companies closed lower on 12 November 2026, with Vectus Biosystems (ASX:VBS) closing at $0.05, down 16.67%, Tissue Repair (ASX:TRP) closing at $0.11, down 15.39%, and Clever Culture Systems (ASX:CC5) closing at $0.014, down 12.50%. The S&P/ASX 200 closed at 9,146.80, lower by about 6.40 points or roughly 0.07%.

Vectus Biosystems (ASX:VBS): FDA Pre-IND Meeting for VB0004

Vectus's quarterly report, dated 29 October 2026, said the US Food and Drug Administration had granted its request for a pre-IND Type B meeting on VB0004 in idiopathic pulmonary fibrosis. Written FDA responses are expected by mid-November 2026. The company has appointed Cardinal Health Regulatory Services as its US regulatory agent to handle FDA communications and submissions.

Vectus completed a Phase Ia study of VB0004 in healthy volunteers, which it said showed a favourable safety and pharmacokinetic profile. The company describes IPF as a progressive disease with significant unmet need.

Tissue Repair (ASX:TRP): US Phase III Wound Trial and 510(k) Plans

Tissue Repair's Appendix 4C, dated 29 October 2026, said about 112 patients had been randomised in its US Phase III chronic wound trial. The company is pursuing a medical device route with a US FDA 510(k) submission targeted for April 2027, and a European CE Mark class II submission to follow.

Cash stood at $4.74 million at quarter end, supplemented by a $1.9 million R&D tax refund received on 1 July 2026. TR Pro+ is now in market in Australia in three formats.

Clever Culture Systems (ASX:CC5): APAS Revolution Funding

Clever Culture announced on 3 November 2026 commitments for a $2.6 million funding package to develop APAS Revolution, a benchtop automated plate assessment system aimed at smaller sterile drug manufacturers. The package includes a targeted $1.0 million Capital raise and a $1.6 million Unsecured Loan due on 30 November 2027.

The company estimates the new product would expand its addressable market by about 50%, to an estimated $4.3 billion, and expects payback on the development to be under two years from launch of the existing APAS Independence system.

Final Word

The three healthcare companies are at different stages, with regulatory feedback, a late-stage trial and a product development funding round all in progress. The share price falls on 12 November came without same-day announcements, and the FDA responses, trial progress and APAS Revolution development will be the next checkpoints.

FAQs

Q: Why did ASX healthcare shares fall on 12 November 2026?

A: All three closed lower, with their updates dated 29 October and 3 November 2026, so the share price moves are not linked to a same-day announcement.

Q: When are the FDA written responses for Vectus expected?

A: Vectus said they are expected by mid-November 2026.

Q: When is the Clever Culture loan due?

A: The $1.6 million unsecured loan is due for repayment on 30 November 2027.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.